FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 317:1114-1121 October 29, 1987 Number 18 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

To investigate the relation between human immunodeficiency virus (HIV) antigenemia and clinical manifestations of HIV infections, we studied 96 patients with hemophilia who were positive for HIV antibody, for a median of 34 months. Every 4 to 10 months a clinical and laboratory examination was performed and serum samples were tested for three HIV markers: HIV antigen, antibody to p24, and antibody to gp41. Twenty-two subjects (23 percent) were found to be positive for HIV antigen: 8 were positive upon entry and remained so (Group 1), and 14 became positive during the study, 4 to 26 months after HIV antibody appeared (seroconversion), 13 of whom remained positive for HIV antigen (Group 2). Most subjects positive for HIV antigen had low or undetectable titers of antibody to p24, whereas the antibody titer to gp41 remained high. In Group 2, patients with low p24 antibody titers had further decreases in their titers before or at the time HIV antigen appeared. Once present, HIV antigen persisted and tended to increase in concentration. In contrast to Group 3 (negative for HIV antigen, low anti-p24 titer) and 4 (negative for HIV antigen, high anti-p24 titer), the groups positive for HIV antigen had significantly higher incidences of acquired immunodeficiency syndrome (P = 0.05), immunodeficiency-related infections (P less than 0.001), and immune thrombocytopenia (P = 0.001), and had more severe disease as measured by the Walter Reed staging system (P less than 0.001). In this study, HIV antigen appeared to be a better predictive marker of HIV-related complications than the absolute T4+ count. These results suggest that HIV antigenemia indicates a poor clinical prognosis.

Source Information

Department of Medical Affairs, Abbott Laboratories, Abbott Park, IL 60064.

This article has been cited by other articles:

• Bogaards, J. A., Goudsmit, J. (2003). Meeting the immense need for HAART in resource-poor settings. J Antimicrob Chemother 52: 743-746 [Full Text]  
• de Baar, M. P., van der Horn, K. H. M., Goudsmit, J., de Ronde, A., de Wolf, F. (1999). Detection of Human Immunodeficiency Virus Type 1 Nucleocapsid Protein p7 In Vitro and In Vivo. J. Clin. Microbiol. 37: 63-67 [Abstract] [Full Text]  
• Rabeneck, L., Wray, N. P. (1993). Predicting the Outcomes of Human Immunodeficiency Virus Infection: How Well Are We Doing?. Arch Intern Med 153: 2749-2755 [Abstract]  
• Gorham, E. D., Garland, F. C., Mayers, D. L., Goforth, R. R., Brodine, S. K., Weiss, P. J., McNally, M. S., Navy Retroviral Working Group, (1993). CD4 Lymphocyte Counts Within 24 Months of Human Immunodeficiency Virus Seroconversion: Findings in the US Navy and Marine Corps. Arch Intern Med 153: 869-876 [Abstract]  
• Sloand, E. M., Pitt, E., Chiarello, R. J., Nemo, G. J. (1991). HIV Testing: State of the Art. JAMA 266: 2861-2866 [Abstract]  
• Gorman, J. M., Kertzner, R., Todak, G., Goetz, R. R., Williams, J. B. W., Rabkin, J., Meyer-Bahlburg, H. F. L., Mayeux, R., Stern, Y., Lange, M., Dobkin, J., Spitzer, R., Ehrhardt, A. A. (1991). Multidisciplinary Baseline Assessment of Homosexual Men With and Without Human Immunodeficiency Virus Infection: I. Overview of Study Design. Arch Gen Psychiatry 48: 120-123 [Abstract]  
• Billings, P. R. (1989). Transfusions and the Acquired Immunodeficiency Syndrome (AIDS). ANN INTERN MED 111: 767-767 [Abstract]  
• Arno, P. S., Shenson, D., Siegel, N. F., Franks, P., Lee, P. R. (1989). Economic and Policy Implications of Early Intervention in HIV Disease. JAMA 262: 1493-1498 [Abstract]  
• Lane, H. C., Falloon, J., Walker, R. E., Deyton, L., Kovacs, J. A., Masur, H., Banks, S., Kirk, L. E., Baseler, M. W., Salzman, N. P., Fauci, A. S. (1989). Zidovudine in Patients with Human Immunodeficiency Virus (HIV) Infection and Kaposi Sarcoma: A Phase II Randomized, Placebo-Controlled Trial. ANN INTERN MED 111: 41-50 [Abstract]  
• Eyster, M. E., Ballard, J. O., Gail, M. H., Drammond, J. E., Goedert, J. J. (1989). Predictive Markers for the Acquired Immunodeficiency Syndrome (AIDS) in Hemophiliacs: Persistence of p24 Antigen and Low T4 Cell Count. ANN INTERN MED 110: 963-969 [Abstract]  
• Levy, J. A. (1989). Human Immunodeficiency Viruses and the Pathogenesis of AIDS. JAMA 261: 2997-3006 [Abstract]  
• Meropol, N. J., Krause, P. R., Ratnoff, O. D., Eyster, M. E., Levine, P. H., White, G. C., Debanne, S., Rowland, D., Lederman, M. M. (1989). Tendency to Serious Sequelae of Infection With the Human Immunodeficiency Virus in Sibships With Hemophilia. Arch Intern Med 149: 885-888 [Abstract]  
• Jackson, J. B., Sannerud, K. J., Hopsicker, J. S., Kwok, S. Y., Edson, J. R., Balfour, H. H. Jr (1988). Hemophiliacs With HIV Antibody Are Actively Infected. JAMA 260: 2236-2239 [Abstract]  
• Chaisson, R. E., Leuther, M. D., Allain, J.-P., Nusinoff-Lehrman, S., Boone, G. S., Feigal, D., Volberding, P. (1988). Effect of Zidovudine on Serum Human Immunodeficiency Virus Core Antigen Levels: Results From a Placebo-Controlled Trial. Arch Intern Med 148: 2151-2153 [Abstract]